chrisvoncsefalvay/vaers-outcomes huggingface dataset:
hot sensation from her pelvic area down to her knee; small capillary type veins(reddish to light purple in color) in the front of her knee that run along the side of her leg.; Side of left leg is purple; Pain; Reddish from her pelvic area down to her knee; Itchy sensation from her pelvic area down to her knee; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (hot sensation from her pelvic area down to her knee), CAPILLARY DISORDER (small capillary type veins(reddish to light purple in color) in the front of her knee that run along the side of her leg.), CONTUSION (Side of left leg is purple), PAIN (Pain) and ERYTHEMA (Reddish from her pelvic area down to her knee) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The medical history was not provided by the reporter.  Concomitant products included GABAPENTIN and PRAVASTATIN for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced FEELING HOT (hot sensation from her pelvic area down to her knee), CAPILLARY DISORDER (small capillary type veins(reddish to light purple in color) in the front of her knee that run along the side of her leg.), CONTUSION (Side of left leg is purple), PAIN (Pain), ERYTHEMA (Reddish from her pelvic area down to her knee) and PRURITUS (Itchy sensation from her pelvic area down to her knee). At the time of the report, FEELING HOT (hot sensation from her pelvic area down to her knee), CAPILLARY DISORDER (small capillary type veins(reddish to light purple in color) in the front of her knee that run along the side of her leg.), CONTUSION (Side of left leg is purple), PAIN (Pain), ERYTHEMA (Reddish from her pelvic area down to her knee) and PRURITUS (Itchy sensation from her pelvic area down to her knee) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-May-2021: Follow-up information received on 09-Jun-2021 included concomitant medication and event pain added.
20 mins after vaccine became nauseated, light headed and chest pain, tightness in central to epigastric area.   VS found she was Orthostatic - BP dropped to 99/55 while standing.  Diabetic.   Chest pain persisted.  Sent to ED
H1N1 vaccine given to L deltoid on 11/5. Mild deltoid pain and L elbow pain same day. Starting 4/ thru 11/ (about 2 wks) L bicep muscle had intermittent trembling/shaking of only bicep. L elbow pain slowly lessened but I continue to have mild L elbow discomfort when lifting lingering L elbow pain.
PAIN IN UPPER LEFT ARM, RED SWOLLEN UPPER LEFT ARM (SITE OF INJECTION), 101 FEVER, CHILLS, SHAKING, SWEATS, ACHY BODY, DIZZINESS, HEADACHE FOR 2 DAYS.
Arm became red, swollen , warm and painful to touch On 11/12/2021 Resident was complaining of not feeling good with dizziness and light headiness.
This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 13:15 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included depression. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 01:00 the patient experienced pins and needles in her fingers and her hands. When she woke up on 03Apr2021 the problem persisted, and she also began to feel weakness and numbness in her hands. It was difficult to grip things, and at night she began to feel pins and needles in her feet, arms, and shoulders. On 04Apr2021 the problem still persisted, although she felt less of a tingling sensation in her shoulders. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event pins and needles in fingers and hands/pins and needles in feet, arms and shoulders/tingling sensation in shoulders, weakness in hands, numbness in hands and difficulty to grip things was not recovered at the time of this report. No follow-up attempts are possible. No further information is expected.
Nausea, Itchy rash at injection site, left arm. Every day it's a bit larger.
12:30am-7:30am- Chills, fever, muscle aches, nausea, fatigue, soreness and red warm skin at injection site. 7:30-2:30pm Extreme fatigue. Temperature variability from fever to normal temp. Slept from 10:00am-2:30 which is extremely abnormal.
Patient had syncopal episode after vaccination.  Had been recently traveling (flew from Spain with minimal food and sleep in last 24 hours).  Patient has history of syncope in the past with Botox injection.  Patient regained consciousness spontaneously.  No seizure activity or head injury.  Symptoms resolved and patient discharged
injection site red; injection site itches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (injection site itches) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041120A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (injection site itches). At the time of the report, VACCINATION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (injection site itches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   Reporter did not allow further contact
Two days post vax, the pt developed an injection site reaction which the reporter did not characterize. That same day the pt was seen by a physician.
4/23/21 at around 1pm, felt pain in left shoulder blade and around left upper lung and ribs area.  Felt like tissues around it was tearing and grinding.  After an hour felt pain near heart area and experienced nausia and felt faint.   Was taken to hospital around 3pm.  Was screened and tested for Covid-19 - negative. XRay was taken - did not show any issues Was given strong anti-inflammatory via shot  Was monitored for 2 hours. Sent home.  Discomfort improved over the weekend and no longer experiencing any symptoms.
Severe pain and numbness on my arm. Chest pain, I thought it was a heart attack.
I had a red circle about one inch around the location of the vaccination and three days of fever and headache. The fever was 101, 102, 100, 102.
Face was pretty red; throat started to tighten; (throat) feeling really scratchy; started to lose voice; inside of my mouth and my lips started getting tangly; (inside of my mouth and my lips) prickly, (inside of my mouth and my lips) non-feeling; vaccination reaction; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Face was pretty red), THROAT TIGHTNESS (throat started to tighten), THROAT IRRITATION ((throat) feeling really scratchy), DYSPHONIA (started to lose voice) and STOMATITIS (inside of my mouth and my lips started getting tangly) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Latex allergy and Allergy (allergic to preservatives).    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Feb-2021, the patient experienced ERYTHEMA (Face was pretty red), THROAT TIGHTNESS (throat started to tighten), THROAT IRRITATION ((throat) feeling really scratchy), DYSPHONIA (started to lose voice), STOMATITIS (inside of my mouth and my lips started getting tangly), HYPOAESTHESIA ORAL ((inside of my mouth and my lips) prickly, (inside of my mouth and my lips) non-feeling) and VACCINATION SITE REACTION (vaccination reaction). The patient was treated with EPINEPHRINE at a dose of half dose. At the time of the report, ERYTHEMA (Face was pretty red), THROAT TIGHTNESS (throat started to tighten), THROAT IRRITATION ((throat) feeling really scratchy), DYSPHONIA (started to lose voice), STOMATITIS (inside of my mouth and my lips started getting tangly), HYPOAESTHESIA ORAL ((inside of my mouth and my lips) prickly, (inside of my mouth and my lips) non-feeling) and VACCINATION SITE REACTION (vaccination reaction) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: normal. On an unknown date, Full blood count: normal. On an unknown date, Oxygen saturation: normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Doctor recommends not to get the second dose and to contact primary doctor and go to an allergist specialist.   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Non-significant Follow up- Contact information updated
pt recvd vax & 2 hrs post vax exp a fever, high pitched cry, & lethargy;pt was treated w/APAP & recovered the following day;pt was only given DT for remaining doses;reporter declined to provide permission for f/u w/patient's MD
Thirteen adult patients in one internal medicine practice site were administered Daptacel brand of DTaP instead of Adacel (Tdap). Also, an adolescent in a second pediatric practice site was administered a different brand of DTaP instead of Tdap. The nomenclature of DTaP and Tdap is confusing and introduces a risk for error, which will only increase as new vaccinations are introduced. In addition, the similarity in the brand names: Daptacel and Adacel is a significant contributing factor to this error as it affected thirteen adult patients. It appears that the internal medicine practice ordered Adacel from the supplier and Daptacel was shipped instead. This error was not identified until thirteen patients were administered this vaccine. All fourteen affected patients were contacted. None of the patients had any unusual vaccine reactions.
Local effects of vaccines. Recommendations: warm compress and clean area well TID, if no improvement or worsening symptoms develop call the office.
Patient reported that injection site area became hard, swollen, red, and warm. area was 3 and 1/2 inches in diameter. The patient reported that she went to urgent care and was told she had cellulitis. She was given an prescriptionfor bactrim ds.
The morning after the last shot my arms, face and head were red like a sun burn. I continue to have deep sores on my arms, face ears and scalp.
expired Moderna COVID-19 booster dose administered greater than 12 hours post puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired Moderna COVID-19 booster dose administered greater than 12 hours post puncture) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016J21-2A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Jan-2022 at 10:05 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired Moderna COVID-19 booster dose administered greater than 12 hours post puncture). On 25-Jan-2022, EXPIRED PRODUCT ADMINISTERED (expired Moderna COVID-19 booster dose administered greater than 12 hours post puncture) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant and treatment medications were reported.  Date the vial  initially stored in the refrigerator  was  21 Jan 2022 at 7:00 AM. Date  and time  vial was first punctured was  24 Jan 2022 at 8:45 AM vial didn't undergo any temperature excursions. Total amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F) 25 hours. The vial was stored post puncture at room  temperature.
Gave pt Hep B vaccine in right deltoid and the SHINGRIX in the left deltoid. I noticed some swelling in her right deltoid, no redness or shortness of breath. I then called the provider in the room.
Reports that approx. 20 minutes after receiving the Hep B vaccine she began experiencing visual disturbances; describes seeing black spots.  Also felt faint, hot, nauseated and felt hot.  She left work shortly afterward and continued to experience these symptoms intermittently throughout the night and until the evening of 3/7/22.  In addition reported that she also experienced mild abdominal cramping 3/7/22 but no diarrhea or vomiting.  States that the symptoms are completely resolved since the evening of 3/7/22.  Did not seek medical attention.
After first vaccine, I went to ER on April 18th with difficulty breathing. Right leg felt a little numb. EKG normal. After second vaccine on April 29th 2021, I had new symptoms for the first time. On May 8th my heartbeat became very high for no reason. Called doctor and went three times to various appointments. Took ECG again. Since heart beats were very high even with light movements, I am wearing a heart monitor for two weeks. I have no pre-existing conditions. All blood work normal.
1/2 hour later (R) arm become painful, 1 1/2 hour later at bedtime (R) was red and swollen, hot to tough, very large red rash next AM. Sweat badly for four days; Temp 102 rash travel down my arm=felt faint weak's. Vaccine information statement=states 2 day 12-19-2017 I went back to my doctor's office on 12-22-2017 because rash and swelling pain was no better. The office person once again it would take 8 day to clear up. It was the worse Christmas I ever had. I will not do the second half of PPSV-23 shot.
nose bleeds mostly early morning (Am); dizziness; high BP; This is a spontaneous report from a contactable consumer received via COVID-19 Vaccine Adverse Event Reporting System . An 81-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number unknown), via an unspecified route of administration, administered in the right arm on 11Feb2021, at 14:30 (at the age of 81 years old) as dose 1, single for COVID-19 immunisation. Medical history included heart problem, hypertension, hypothyroidism, back pain, and known allergies: fish. She was not pregnant at the time of report. Concomitant medications included tramadol, lorazepam, atorvastatin calcium (LIPITOR), paracetamol (TYLENOL), and levothyroxine sodium (LEVOTHYROXIN). The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Feb2021, at 09:00, the patient experienced nose bleeds mostly early morning (Am), dizziness, and high BP. The patient was not diagnosed with COVID-19 prior to vaccination and she has not been tested for COVID-19 since the vaccination. No therapeutic measures were taken as a result of the events. The patient has not recovered from the events at the time of report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
OFF LABEL USE; VACCINE ADMINISTERED TO A MINOR; This spontaneous report received from a pharmacist concerned a 12 year old male. The patient's weight was 280 pounds, and height was 74 inches. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, expiry: UNKNOWN) dose was not reported, administered on 17-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 17-SEP-2021, the patient experienced off label use. On 17-SEP-2021, the patient experienced vaccine administered to a minor. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the off label use and vaccine administered to a minor was not reported. This report was non-serious.
Patient reported "tingly" sensation in mouth and itching on forearms within 30 minutes of vaccination.  Symptoms reduced without treatment and patient was released to home.
pt bowel movement was cream/grey colored w/green wax-like pea sized chunks;deficated a large amount of this;also got pink eye;diarrhea;
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On an unknown date in 2013, the patient was inoculated with ZOSTAVAX as recommended for routine adult health maintenance for the prevention of shingles (strength, dose number, anatomical location, route of administration, lot number and expiration date were not reported). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 24-SEP-2014, the patient was treated for onset of a severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related.
Felt a little achy took an Advil and feel fine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient (not pregnant) received bnt162b2 (BNT162B2), administration date Mar2021 (Lot number: Unknown) as single dose and (Batch/Lot number: unknown) for covid-19 immunisation. Relevant medical history included: "UNKNOWN" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose), for COVID-19 immunization. The following information was reported: PAIN (non-serious) with onset 2021, outcome "recovered" (2021), described as "Felt a little achy took an Advil and feel fine". Therapeutic measures were taken as a result of pain. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a health professional concerning a 33 year old female who on 07-DEC-2007 was vaccinated IM in the left deltoid with the first dose of Gardasil (659055/1522U).  On 07-DEC-2007 the patient experienced injection site pain. The patient's injection site pain started shortly after vaccination with Gardasil and resolved the next day.  On 08-DEC-2007 the patient experienced body rash, muscle aches and malaise.  The rash on the patient's chest was the size of her palm, red and itchy.  After the rash the patient developed muscle aches over the whole body and flu-like symptoms.  The patient stated that "she felt like she was run over by a truck".  The muscle aches and flu symptoms resolved by 10-DEC-2007.  The patient still has the rash as of 11-DEC-2007.  The patient sought unspecified medical attention.  There is no other information to report.  Additional information has been requested.
This spontaneous report as received from a registered nurse (R.N.) refers to a 13 years old patient of unknown gender. Pertinent medical history and drug reactions/allergies were not reported. The patient received first dose GARDASIL (dose, route, lot# and expiration date were not reported) in 2012. The reporter stated that the patient received "catch up dose" (dose 2) (dose, route, lot# and expiration date were not reported) on 11-JAN-2016 and third dose (Lot K007264 expiration date 02-MAR-2017, dose and route were not reported) on 14-MAR-2016 (inappropriate schedule of drug administration). No adverse effects were reported. Additional information has been requested.
22MAY95 recvd 3rd vax-no prev rxn;24MAY95-PM c/o aching pain lt arm from elbow to shoulder;24MAY95 pain in neck & lower back;to use hot compresses & Ibuprofen
In addition to injection site soreness, I started experiencing significant malaise 20 hours after the shot, at 22 hours after the shot temperature was 100.8 F with shaking chills and body aches, at 24 hours after the shot temperature was 102.4 F with shaking chills and body aches. Treated fever with Tylenol. Temperature was reduced to 101.3 and stayed around there the rest  of the day with occasional chills as Tylenol wore off.  Lymph node in left arm pit became swollen by 36 hours after the shot but fever, body aches dissipated by 48 hours after the shot. After this there were no further fever or aches and felt substantially better except for a little weakness. By 72 hours after the shot only minor muscle soreness at the injection site and lesser swelling of the lymph node in the left arm pit with no other symptoms.
reaction to an Influenza vaccine; Initial information received on 05-Feb-2021 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves an adult patient who experienced reaction to an influenza vaccine (vaccination complication), while he/she received vaccine INFLUENZA VACCINE.   The patient's past vaccination(s) included INFLUENZA VACCINE in JUN-2018 and PNEUMO 23. The patient's medical history, past medical treatment(s) and family history were not provided.   On an 29-Nov-2018, the patient received a 0.5 mL dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot JD029AB and expiry date 05-Feb-2019) via intramuscular route in deltoid for prophylactic vaccination.  On an unknown date, the patient developed a non-serious reaction to an influenza vaccine (vaccination complication) (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported that the patient had a reaction to an Influenza vaccine that was received in 2018 and also another vaccine Pneumo. It was not a severe reaction. This came up in conversation as the COVID vaccine was being discussed.  No relevant laboratory tests were reported   It was not reported if the patient received a corrective treatment.  The patient outcome is reported as unknown for reaction to an influenza vaccine.
Bell's Palsy; generalized weakness- diagnosed as Guillain Barre' syndrome by MD
Inflammatory lesion in site of vaccination noticed 2 days ago, no fever, lesions are spreading.
fever,diarrhea,vomiting,nose bleed,chills,body aches,weakness,dizziness and dry lips.